Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches
Biosimilars Business Reports 9% YoY Growth As Fully Integrated Company
With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.
